Update on novel, validly published, and included bacterial taxa derived from human clinical specimens and taxonomic revisions published in 2025

ABSTRACT This review summarizes novel taxon designations ascribed to prokaryotes derived from human primary clinical material during calendar year 2025, as well as proposed revisions to existing taxonomy. Major activity took place in the Streptococcus genus, as more than one dozen novel species were validly and effectively published, with two of these later classified as synonyms of Streptococcus thalassemiae . Moreover, whole genome sequencing and phylogenetic investigation of Streptococcus mitis group organisms resulted in a proposal to designate five species-level Streptococcus spp. taxa as Streptococcus mitis and an additional taxon as Streptococcus oralis subsp. dentisani . More than one dozen taxa were newly included in order Enterobacterales in 2025. Select novel taxa within genera Providencia and Enterobacter commonly possessed genotypes that conferred resistance to carbapenem and/or higher-generation cephem agents. Stenotrophomonas muris sp. nov. and Terrisporobacter muris sp. nov., initially characterized in gnotobiotic murine systems within the past 4 years, had clinical significance in human infection that was demonstrated in primary literature. The vast majority of the more than 70 novel obligate anaerobic taxa were derived from microbiome studies and had little ascribed clinical significance. Four novel obligate anaerobic Gram-negative taxa were shown to be of greater abundance in persons with Parkinson’s disease than in those without. Updates to taxa previously published in the Journal of Clinical Microbiology compendia reveal that several could serve as reservoirs for multiple antimicrobial resistance determinants. One example is the non-glucose fermentative Gram-negative bacillus Pseudomonas juntendi .